Promoter Methylation of MMP9 and RUNX3: Diagnostic Potential and Clinical Associations in Rheumatoid Arthritis
The study suggests that <i>MMP9</i> promoter hypomethylation may serve as a promising diagnostic and prognostic biomarker for RA. In addition, <i>RUNX3</i> promoter methylation showed potential for assessing disease activity. These findings have the potential to improve the diagnosis and prognosis of RA, contributing to improved clinical management of patients.
Authors
- Seyyed Mohamad Hoseini
- Shahrouz Khoshbakht (ORCID: https://orcid.org/0000-0003-0395-4152)
- A. Dabagh Moghadam
- Meysam Mosallaei (ORCID: https://orcid.org/0000-0001-8528-699X)
- Ali Zarei
- Ruhollah Mirjani
- Mohsen Ghasemzadeh Soroush
- Yousef Mohammadi
Institutions
- Arak University of Medical Sciences (IR)
- Aja University of Medical Sciences (IR)
- Imam Reza Hospital (IR)
- Semnan University of Medical Sciences (IR)
- University of Social Welfare and Rehabilitation Sciences (IR)
Publication Details
- Journal
- Advanced Biomedical Research
- Published
- 2025-12-01
- DOI
- https://doi.org/10.4103/abr.abr_398_25
- Primary Topic
- Rheumatoid Arthritis Research and Therapies
- Type
- article
- Field-Weighted Citation Impact
- 0.00